More Articles


Reimagining the life sciences beyond COVID-19

Blair Gottscho, (Nov 17, 2020)

A new report from Reuters Events Pharma and EY reveals the impacts on the life sciences sector and analyses the road ahead

Automation is key in cell and gene therapy manufacturing

Andrew Stone, (Oct 30, 2020)

Although the list of cell and gene therapies is growing, prices remain high. Now developers are working on a road map to streamline production and drop costs

How sustainable is remote health at scale?

Nicola Davies, (Oct 28, 2020)

Remote health has proved its worth to the entire healthcare sector but sustaining and scaling it requires work from every stakeholder
Patients and Medical

Digital companions: helping improve patient treatment journeys

Katie Osborne, (Oct 23, 2020)

The virtual health explosion isn't going away. This just at the start of an era of digital enhancement
Patients and Medical

Racially diverse clinical trials: A new patient-led legacy takes root

Andrew Stone, (Oct 15, 2020)

Attempts to make trials more diverse aren’t working. To overcome far-reaching inequality and deep distrust, pharma must be educated by, as well as educate, under-served communities
Patients and Medical

Patient engagement: Breaking through in digital

Andrew Stone, (Oct 14, 2020)

The pandemic is serving as an accelerated lesson in the possibilities of digital engagement. Now pharma must work out how to harness its full potential

Adapting to the multichannel imperative: A special report

Andrew Stone, (Oct 8, 2020)

Pharma’s gradual evolution into digital-first commercial has become urgent in the COVID-19 world. A comprehensive multi-channel approach including the use of digital tools to enhance customer engagement will transform pharma sales.

COVID-19: The tipping point for rapid tech adoption

Andrew Stone, (Oct 2, 2020)

A new pandemic-driven technological revolution is reshaping the entire healthcare system in 2020 and everyone’s sense of what is possible beyond it
Patients and Medical

Amplifying the patient voice in rare disease access

Elly Aylwin-Foster, (Oct 2, 2020)

Rare disease patients are organising like never before, turning up the publicity volume and becoming ever more active in driving cures in the lab and even the boardroom
Patients and Medical

From complexity to clarity in cell and gene therapy

Andrew Stone, (Sep 16, 2020)

Breakthrough CGT therapies are coming thick and fast, now pharma must work on multiple fronts to educate non-specialist stakeholders about their exciting possibilities